Is HURA or CBIO more profitable?

Crescent Biopharma's return on equity of -101.50% beat TuHURA Biosciences' return on equity. Company Net Margins Return on Equity Return on Assets TuHURA Biosciences N/A -156.47% -106.98% Crescent Biopharma N/A -101.50% -86.86%

Is HURA or CAPR more profitable?

Capricor Therapeutics' return on equity of -56.60% beat TuHURA Biosciences' return on equity. Company Net Margins Return on Equity Return on Assets TuHURA Biosciences N/A -156.47% -106.98% Capricor Therapeutics N/A -56.60% -43.97%

Do analysts prefer YDES or HURA?

TuHURA Biosciences has a consensus target price of $9.00, suggesting a potential upside of 371.20%. Given TuHURA Biosciences' stronger consensus rating and higher probable upside, analysts clearly believe TuHURA Biosciences is more favorable than YD Bio. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score YD Bio 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 TuHURA Biosciences 1 Sell rating(s) 0 Hold rating(s) 5 Buy rating(s) 0 Strong Buy rating(s) 2.67

Which has better earnings and valuation, YDES or HURA?

Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio YD Bio N/A N/A N/A N/A N/A TuHURA Biosciences N/A N/A -$30.05M -$0.54 N/A

Is YDES or HURA more profitable?

YD Bio's return on equity of 0.00% beat TuHURA Biosciences' return on equity. Company Net Margins Return on Equity Return on Assets YD Bio N/A N/A N/A TuHURA Biosciences N/A -156.47% -106.98%

Is HURA or KMDA more profitable?

Kamada has a net margin of 11.60% compared to TuHURA Biosciences' net margin of 0.00%. Kamada's return on equity of 8.37% beat TuHURA Biosciences' return on equity. Company Net Margins Return on Equity Return on Assets TuHURA Biosciences N/A -156.47% -106.98% Kamada 11.60% 8.37% 5.85%

TuHURA Biosciences (HURA) Competitors

$1.91 -0.07 (-3.54%)

Closing price 10/2/2026 04:00 PM Eastern

Extended Trading

$1.95 +0.04 (+2.09%)

As of 10/2/2026 07:30 PM Eastern

Compare

HURA vs. CBIO, CAPR, YDES, PBYI, and KMDA

Should you buy TuHURA Biosciences stock or one of its competitors? TuHURA Biosciences's main competitors and comparable companies include Crescent Biopharma (CBIO), Capricor Therapeutics (CAPR), YD Bio (YDES), Puma Biotechnology (PBYI), and Kamada (KMDA). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does TuHURA Biosciences compare to Crescent Biopharma?

TuHURA Biosciences (NASDAQ:HURA) and Crescent Biopharma (NASDAQ:CBIO) are both small-cap healthcare companies, but which is the superior investment? We will compare the two businesses based on the strength of their risk, earnings, profitability, dividends, analyst recommendations, valuation, media sentiment and institutional ownership.

In the previous week, Crescent Biopharma had 2 more articles in the media than TuHURA Biosciences. MarketBeat recorded 2 mentions for Crescent Biopharma and 0 mentions for TuHURA Biosciences. Crescent Biopharma's average media sentiment score of 0.37 beat TuHURA Biosciences' score of 0.00 indicating that Crescent Biopharma is being referred to more favorably in the news media.

Company	Overall Sentiment
TuHURA Biosciences	Neutral
Crescent Biopharma	Neutral

0.6% of TuHURA Biosciences shares are owned by institutional investors. Comparatively, 75.2% of Crescent Biopharma shares are owned by institutional investors. 6.1% of TuHURA Biosciences shares are owned by company insiders. Comparatively, 24.8% of Crescent Biopharma shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Crescent Biopharma's return on equity of -101.50% beat TuHURA Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
TuHURA Biosciences	N/A	-156.47%	-106.98%
Crescent Biopharma	N/A	-101.50%	-86.86%

TuHURA Biosciences currently has a consensus price target of $9.00, indicating a potential upside of 371.20%. Crescent Biopharma has a consensus price target of $29.60, indicating a potential upside of 106.70%. Given TuHURA Biosciences' higher possible upside, analysts clearly believe TuHURA Biosciences is more favorable than Crescent Biopharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
TuHURA Biosciences	1 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.67
Crescent Biopharma	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	2 Strong Buy rating(s)	2.83

TuHURA Biosciences has higher earnings, but lower revenue than Crescent Biopharma. TuHURA Biosciences is trading at a lower price-to-earnings ratio than Crescent Biopharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
TuHURA Biosciences	N/A	N/A	-$30.05M	-$0.54	N/A
Crescent Biopharma	$10.84M	49.06	-$153.94M	-$6.72	N/A

TuHURA Biosciences has a beta of -0.21, meaning that its stock price is 121% less volatile than the broader market. Comparatively, Crescent Biopharma has a beta of 1.27, meaning that its stock price is 27% more volatile than the broader market.

Summary

Crescent Biopharma beats TuHURA Biosciences on 11 of the 15 factors compared between the two stocks.

How does TuHURA Biosciences compare to Capricor Therapeutics?

TuHURA Biosciences (NASDAQ:HURA) and Capricor Therapeutics (NASDAQ:CAPR) are both small-cap healthcare companies, but which is the better business? We will compare the two companies based on the strength of their media sentiment, institutional ownership, valuation, risk, analyst recommendations, profitability, dividends and earnings.

TuHURA Biosciences has higher earnings, but lower revenue than Capricor Therapeutics. Capricor Therapeutics is trading at a lower price-to-earnings ratio than TuHURA Biosciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
TuHURA Biosciences	N/A	N/A	-$30.05M	-$0.54	N/A
Capricor Therapeutics	$22.27M	23.37	-$105.04M	-$2.45	N/A

TuHURA Biosciences presently has a consensus target price of $9.00, indicating a potential upside of 371.20%. Capricor Therapeutics has a consensus target price of $30.25, indicating a potential upside of 237.99%. Given TuHURA Biosciences' stronger consensus rating and higher probable upside, equities analysts clearly believe TuHURA Biosciences is more favorable than Capricor Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
TuHURA Biosciences	1 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.67
Capricor Therapeutics	1 Sell rating(s)	6 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.27

TuHURA Biosciences has a beta of -0.21, indicating that its share price is 121% less volatile than the broader market. Comparatively, Capricor Therapeutics has a beta of 0.61, indicating that its share price is 39% less volatile than the broader market.

0.6% of TuHURA Biosciences shares are owned by institutional investors. Comparatively, 21.7% of Capricor Therapeutics shares are owned by institutional investors. 6.1% of TuHURA Biosciences shares are owned by insiders. Comparatively, 9.2% of Capricor Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Capricor Therapeutics' return on equity of -56.60% beat TuHURA Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
TuHURA Biosciences	N/A	-156.47%	-106.98%
Capricor Therapeutics	N/A	-56.60%	-43.97%

In the previous week, Capricor Therapeutics had 12 more articles in the media than TuHURA Biosciences. MarketBeat recorded 12 mentions for Capricor Therapeutics and 0 mentions for TuHURA Biosciences. Capricor Therapeutics' average media sentiment score of 0.10 beat TuHURA Biosciences' score of 0.00 indicating that Capricor Therapeutics is being referred to more favorably in the news media.

Company	Overall Sentiment
TuHURA Biosciences	Neutral
Capricor Therapeutics	Neutral

Summary

Capricor Therapeutics beats TuHURA Biosciences on 8 of the 14 factors compared between the two stocks.

How does TuHURA Biosciences compare to YD Bio?

YD Bio (NASDAQ:YDES) and TuHURA Biosciences (NASDAQ:HURA) are both small-cap healthcare companies, but which is the better investment? We will compare the two companies based on the strength of their institutional ownership, profitability, valuation, analyst recommendations, dividends, media sentiment, earnings and risk.

YD Bio's return on equity of 0.00% beat TuHURA Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
YD Bio	N/A	N/A	N/A
TuHURA Biosciences	N/A	-156.47%	-106.98%

In the previous week, YD Bio's average media sentiment score of 0.00 equaled TuHURA Biosciences'average media sentiment score.

Company	Overall Sentiment
YD Bio	Neutral
TuHURA Biosciences	Neutral

TuHURA Biosciences has a consensus target price of $9.00, suggesting a potential upside of 371.20%. Given TuHURA Biosciences' stronger consensus rating and higher probable upside, analysts clearly believe TuHURA Biosciences is more favorable than YD Bio.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
YD Bio	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
TuHURA Biosciences	1 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.67

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
YD Bio	N/A	N/A	N/A	N/A	N/A
TuHURA Biosciences	N/A	N/A	-$30.05M	-$0.54	N/A

0.6% of TuHURA Biosciences shares are owned by institutional investors. 6.1% of TuHURA Biosciences shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

YD Bio has a beta of -1.55, suggesting that its share price is 255% less volatile than the broader market. Comparatively, TuHURA Biosciences has a beta of -0.21, suggesting that its share price is 121% less volatile than the broader market.

Summary

TuHURA Biosciences beats YD Bio on 6 of the 8 factors compared between the two stocks.

How does TuHURA Biosciences compare to Puma Biotechnology?

TuHURA Biosciences (NASDAQ:HURA) and Puma Biotechnology (NASDAQ:PBYI) are both small-cap healthcare companies, but which is the superior investment? We will contrast the two companies based on the strength of their media sentiment, risk, valuation, profitability, analyst recommendations, dividends, earnings and institutional ownership.

0.6% of TuHURA Biosciences shares are owned by institutional investors. Comparatively, 61.3% of Puma Biotechnology shares are owned by institutional investors. 6.1% of TuHURA Biosciences shares are owned by company insiders. Comparatively, 22.2% of Puma Biotechnology shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

TuHURA Biosciences has a beta of -0.21, indicating that its share price is 121% less volatile than the broader market. Comparatively, Puma Biotechnology has a beta of 1.22, indicating that its share price is 22% more volatile than the broader market.

Puma Biotechnology has higher revenue and earnings than TuHURA Biosciences. TuHURA Biosciences is trading at a lower price-to-earnings ratio than Puma Biotechnology, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
TuHURA Biosciences	N/A	N/A	-$30.05M	-$0.54	N/A
Puma Biotechnology	$228.40M	2.15	$31.11M	$0.52	18.29

TuHURA Biosciences currently has a consensus price target of $9.00, suggesting a potential upside of 371.20%. Puma Biotechnology has a consensus price target of $6.00, suggesting a potential downside of 36.91%. Given TuHURA Biosciences' stronger consensus rating and higher possible upside, equities analysts clearly believe TuHURA Biosciences is more favorable than Puma Biotechnology.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
TuHURA Biosciences	1 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.67
Puma Biotechnology	0 Sell rating(s)	2 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	2.00

Puma Biotechnology has a net margin of 11.50% compared to TuHURA Biosciences' net margin of 0.00%. Puma Biotechnology's return on equity of 20.76% beat TuHURA Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
TuHURA Biosciences	N/A	-156.47%	-106.98%
Puma Biotechnology	11.50%	20.76%	13.22%

In the previous week, Puma Biotechnology had 1 more articles in the media than TuHURA Biosciences. MarketBeat recorded 1 mentions for Puma Biotechnology and 0 mentions for TuHURA Biosciences. TuHURA Biosciences' average media sentiment score of 0.00 equaled Puma Biotechnology'saverage media sentiment score.

Company	Overall Sentiment
TuHURA Biosciences	Neutral
Puma Biotechnology	Neutral

Summary

Puma Biotechnology beats TuHURA Biosciences on 11 of the 14 factors compared between the two stocks.

How does TuHURA Biosciences compare to Kamada?

TuHURA Biosciences (NASDAQ:HURA) and Kamada (NASDAQ:KMDA) are both small-cap healthcare companies, but which is the better stock? We will compare the two businesses based on the strength of their media sentiment, valuation, profitability, dividends, analyst recommendations, risk, earnings and institutional ownership.

Kamada has higher revenue and earnings than TuHURA Biosciences. TuHURA Biosciences is trading at a lower price-to-earnings ratio than Kamada, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
TuHURA Biosciences	N/A	N/A	-$30.05M	-$0.54	N/A
Kamada	$191.85M	2.49	$20.20M	$0.38	21.87

0.6% of TuHURA Biosciences shares are held by institutional investors. Comparatively, 20.4% of Kamada shares are held by institutional investors. 6.1% of TuHURA Biosciences shares are held by insiders. Comparatively, 36.1% of Kamada shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

TuHURA Biosciences has a beta of -0.21, suggesting that its share price is 121% less volatile than the broader market. Comparatively, Kamada has a beta of 0.89, suggesting that its share price is 11% less volatile than the broader market.

In the previous week, Kamada had 9 more articles in the media than TuHURA Biosciences. MarketBeat recorded 9 mentions for Kamada and 0 mentions for TuHURA Biosciences. TuHURA Biosciences' average media sentiment score of 0.00 beat Kamada's score of -0.38 indicating that TuHURA Biosciences is being referred to more favorably in the media.

Company	Overall Sentiment
TuHURA Biosciences	Neutral
Kamada	Neutral

TuHURA Biosciences currently has a consensus price target of $9.00, suggesting a potential upside of 371.20%. Kamada has a consensus price target of $13.50, suggesting a potential upside of 62.45%. Given TuHURA Biosciences' higher probable upside, analysts clearly believe TuHURA Biosciences is more favorable than Kamada.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
TuHURA Biosciences	1 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.67
Kamada	0 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	3.00

Kamada has a net margin of 11.60% compared to TuHURA Biosciences' net margin of 0.00%. Kamada's return on equity of 8.37% beat TuHURA Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
TuHURA Biosciences	N/A	-156.47%	-106.98%
Kamada	11.60%	8.37%	5.85%

Summary

Kamada beats TuHURA Biosciences on 12 of the 15 factors compared between the two stocks.

Get TuHURA Biosciences News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding HURA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

HURA vs. The Competition

Export

Metric	TuHURA Biosciences	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$121.72M	$3.86B	$7.16B	$13.28B
Dividend Yield	N/A	3.65%	2.54%	17.32%
P/E Ratio	-3.54	13.06	275.66	26.04
Price / Sales	N/A	1,292.11	608.92	91.72
Price / Cash	N/A	123.39	78.87	52.62
Price / Book	5.62	16.63	10.93	6.31
Net Income	-$30.05M	-$22.71M	$3.51B	$362.16M
7 Day Performance	-9.05%	-2.99%	-2.00%	-1.66%
1 Month Performance	-10.75%	-10.81%	-6.19%	-4.68%
1 Year Performance	-26.54%	19.19%	8.03%	1.57%

TuHURA Biosciences Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
HURA TuHURA Biosciences	1.1662 of 5 stars	$1.91 -3.5%	$9.00 +371.2%	-26.5%	$121.72M	N/A	N/A	22	Positive News
CBIO Crescent Biopharma	2.7298 of 5 stars	$14.35 -1.2%	$29.60 +106.3%	+22.2%	$532.77M	$10.84M	N/A	44
CAPR Capricor Therapeutics	3.1551 of 5 stars	$8.88 +2.0%	$30.25 +240.7%	+21.6%	$515.64M	$22.27M	N/A	231	Gap Up
YDES YD Bio	N/A	$7.23 +1.6%	N/A	N/A	$511.46M	N/A	N/A	15
PBYI Puma Biotechnology	0.6772 of 5 stars	$9.75 -0.7%	$6.00 -38.5%	+85.4%	$503.97M	$228.40M	18.78	179

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:HURA) was last updated on 10/4/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

TuHURA Biosciences (HURA) Competitors

HURA vs. CBIO, CAPR, YDES, PBYI, and KMDA

How does TuHURA Biosciences compare to Crescent Biopharma?

Summary

How does TuHURA Biosciences compare to Capricor Therapeutics?

Summary

How does TuHURA Biosciences compare to YD Bio?

Summary

How does TuHURA Biosciences compare to Puma Biotechnology?

Summary

How does TuHURA Biosciences compare to Kamada?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

HURA vs. The Competition

TuHURA Biosciences Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

TuHURA Biosciences (HURA) Competitors

HURA vs. CBIO, CAPR, YDES, PBYI, and KMDA

How does TuHURA Biosciences compare to Crescent Biopharma?

Does the media favor HURA or CBIO?

Do insiders & institutionals have more ownership in HURA or CBIO?

Is HURA or CBIO more profitable?

Do analysts prefer HURA or CBIO?

Which has better valuation and earnings, HURA or CBIO?

Which has more risk and volatility, HURA or CBIO?

Summary

How does TuHURA Biosciences compare to Capricor Therapeutics?

Which has stronger earnings & valuation, HURA or CAPR?

Do analysts recommend HURA or CAPR?

Which has more risk & volatility, HURA or CAPR?

Do institutionals and insiders have more ownership in HURA or CAPR?

Is HURA or CAPR more profitable?

Does the media favor HURA or CAPR?

Summary

How does TuHURA Biosciences compare to YD Bio?

Is YDES or HURA more profitable?

Does the media refer more to YDES or HURA?

Do analysts prefer YDES or HURA?

Which has better earnings and valuation, YDES or HURA?

Do institutionals and insiders have more ownership in YDES or HURA?

Which has more volatility and risk, YDES or HURA?

Summary

How does TuHURA Biosciences compare to Puma Biotechnology?

Do insiders & institutionals hold more shares of HURA or PBYI?

Which has more volatility & risk, HURA or PBYI?

Which has better valuation & earnings, HURA or PBYI?

Do analysts prefer HURA or PBYI?

Is HURA or PBYI more profitable?

Does the media favor HURA or PBYI?

Summary

How does TuHURA Biosciences compare to Kamada?

Which has better valuation & earnings, HURA or KMDA?

Do insiders and institutionals have more ownership in HURA or KMDA?

Which has more volatility and risk, HURA or KMDA?

Does the media prefer HURA or KMDA?

Do analysts prefer HURA or KMDA?

Is HURA or KMDA more profitable?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

HURA vs. The Competition

TuHURA Biosciences Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools